Literature DB >> 2621245

Spontaneous production of bone-resorbing lymphokines by B cells in patients with systemic lupus erythematosus.

Y Tanaka1, K Watanabe, M Suzuki, K Saito, S Oda, H Suzuki, S Eto, U Yamashita.   

Abstract

The culture supernatant of B cells from patients with active systemic lupus erythematosus (SLE) who had never been treated with corticosteroids had bone-resorbing activity (BRA) which stimulated the 45Ca release from prelabeled murine fetal bones. Then we studied the characteristics and the relationship of this BRA with several lymphokines previously reported. The BRA was eluted as three peaks at approximately 17,000, 35,000, and 80,000 daltons by Sephacryl S-200 column chromatography. Recombinant (r)IL 1 alpha, rIL 1 beta, and rTNF possessed BRA, but rIL 4 and rIL 6 did not. Furthermore, the BRA from SLE B cells was absorbed with anti-IL 1 alpha antibody but not with anti-IL 1 beta and anti-TNF antibody. Therefore, the fact that SLE B cells produce BRA which corresponds to IL 1 alpha and IL 1 alpha produced by B cells might be one of the causes of bone destruction in SLE patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2621245     DOI: 10.1007/bf00917107

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  43 in total

1.  Cloning and characterization of the cDNAs for human and rabbit interleukin-1 precursor.

Authors:  Y Furutani; M Notake; M Yamayoshi; J Yamagishi; H Nomura; M Ohue; R Furuta; T Fukui; M Yamada; S Nakamura
Journal:  Nucleic Acids Res       Date:  1985-08-26       Impact factor: 16.971

2.  Bone-resorbing activity in supernatants from lymphoid cell lines.

Authors:  G R Mundy; R A Luben; L G Raisz; J J Oppenheim; D N Buell
Journal:  N Engl J Med       Date:  1974-04-18       Impact factor: 91.245

3.  Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes.

Authors:  J E Horton; L G Raisz; H A Simmons; J J Oppenheim; S E Mergenhagen
Journal:  Science       Date:  1972-09-01       Impact factor: 47.728

4.  Purification and physico-chemical characterization of rabbit tumor necrosis factor.

Authors:  M R Ruff; G E Gifford
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

5.  Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus.

Authors:  Y Tanaka; K Saito; F Shirakawa; T Ota; H Suzuki; S Eto; U Yamashita
Journal:  J Immunol       Date:  1988-11-01       Impact factor: 5.422

6.  Avascular necrosis in SLE. An apparent predilection for young patients.

Authors:  F E Smith; D E Sweet; C M Brunner; J S Davis
Journal:  Ann Rheum Dis       Date:  1976-06       Impact factor: 19.103

7.  An interleukin 1 like factor stimulates bone resorption in vitro.

Authors:  M Gowen; D D Wood; E J Ihrie; M K McGuire; R G Russell
Journal:  Nature       Date:  1983 Nov 24-30       Impact factor: 49.962

8.  Reduced function of HLA-DR-positive monocytes in patients with systemic lupus erythematosus (SLE).

Authors:  F Shirakawa; U Yamashita; H Suzuki
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

9.  Two interleukin 1 genes in the mouse: cloning and expression of the cDNA for murine interleukin 1 beta.

Authors:  P W Gray; D Glaister; E Chen; D V Goeddel; D Pennica
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

10.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

View more
  9 in total

1.  Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus.

Authors:  Makio Furukawa; Chikako Kiyohara; Hiroshi Tsukamoto; Hiroki Mitoma; Yasutaka Kimoto; Ayumi Uchino; Misato Nakagawa; Kensuke Oryoji; Terufumi Shimoda; Koichi Akashi; Mine Harada; Takahiko Horiuchi
Journal:  Rheumatol Int       Date:  2009-12-18       Impact factor: 2.631

2.  Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls.

Authors:  I M Gilboe; T K Kvien; G Haugeberg; G Husby
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

3.  Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Hilda Sandoval-Cruz; Ricardo O Escárcega; Mario Jiménez-Hernández; Ivet Etchegaray-Morales; Elena Soto-Vega; Margarita Muñoz-Guarneros; Aurelio López-Colombo; Margarita Delezé-Hinojosa; Ricard Cervera
Journal:  Clin Rheumatol       Date:  2008-08-01       Impact factor: 2.980

Review 4.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

5.  Urinary excretion of the pyridinium cross-links of collagen in systemic lupus erythematosus.

Authors:  Y Kipen; R Will; B J Strauss; E F Morand
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

6.  Loss of bone mineral density in premenopausal women with systemic lupus erythematosus.

Authors:  F Formiga; I Moga; J M Nolla; M Pac; F Mitjavila; D Roig-Escofet
Journal:  Ann Rheum Dis       Date:  1995-04       Impact factor: 19.103

7.  Prevalence and Risk Factors of Reduced Bone Mineral Density in Systemic Lupus Erythematosus Patients: A Meta-Analysis.

Authors:  Jumei Xia; Ran Luo; Shuiming Guo; Yi Yang; Shuwang Ge; Gang Xu; Rui Zeng
Journal:  Biomed Res Int       Date:  2019-02-20       Impact factor: 3.411

Review 8.  Microarray profiling of lymphocytes in internal diseases with an altered immune response: potential and methodology.

Authors:  Anatoliy Gladkevich; S Adriaan Nelemans; Henk F Kauffman; Jakob Korf
Journal:  Mediators Inflamm       Date:  2005-12-14       Impact factor: 4.711

Review 9.  Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus.

Authors:  Timothy A Gottschalk; Evelyn Tsantikos; Margaret L Hibbs
Journal:  Front Immunol       Date:  2015-10-28       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.